{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0005105,73,MONDO:0005105,37,0]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0005105","source":"MONDO:0005105|melanoma","targets":["NCT00324272|Post-Operative Drainage Following Lymph Node Dissection|COMPLETED|PHASE4|INTERVENTIONAL","NCT01053819|Can We Miss Pigmented Lesions in Psoriasis Patients?|COMPLETED|PHASE4|INTERVENTIONAL","NCT01898585|An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma|COMPLETED|PHASE4|INTERVENTIONAL","NCT02068196|A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT02451488|Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma|COMPLETED|PHASE4|INTERVENTIONAL","NCT03313544|Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03340506|Dabrafenib and/or Trametinib Rollover Study|RECRUITING|PHASE4|INTERVENTIONAL","NCT03715205|Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)|COMPLETED|PHASE4|INTERVENTIONAL","NCT04261179|Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05467137|Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06116461|Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response|RECRUITING|PHASE4|INTERVENTIONAL","NCT06785974|Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT07004335|Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT00001296|A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00002455|Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00002763|High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00002767|Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00002882|Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00002892|Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003027|Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003444|Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003641|High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT00003647|Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003789|Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg|COMPLETED|PHASE3|INTERVENTIONAL","NCT00004196|Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis|COMPLETED|PHASE3|INTERVENTIONAL","NCT00005052|Vaccine Therapy in Treating Patients With Primary Stage II Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00006237|S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00006249|Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00016263|Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00019682|Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00020839|Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain|TERMINATED|PHASE3|INTERVENTIONAL","NCT00039000|Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00039234|Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00052130|Vaccine Therapy for Patients With Stage III Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00052156|Vaccine Therapy for Patients With Stage IV Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00055562|Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00057616|Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.|COMPLETED|PHASE3|INTERVENTIONAL","NCT00072124|Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00087776|Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT00091572|Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00094653|MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00110019|Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|COMPLETED|PHASE3|INTERVENTIONAL","NCT00111007|A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00200577|Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00204529|Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB|COMPLETED|PHASE3|INTERVENTIONAL","NCT00221702|PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00226408|Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00257205|CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy|COMPLETED|PHASE3|INTERVENTIONAL","NCT00275496|Multicenter Selective Lymphadenectomy Trial (MSLT)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00287196|Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes|COMPLETED|PHASE3|INTERVENTIONAL","NCT00324155|Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00324727|Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00434057|Evaluation of Pigmented Skin Lesions With MelaFind(R) System|COMPLETED|PHASE3|INTERVENTIONAL","NCT00447356|High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT00477906|M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00518895|Trial of Dacarbazine With or Without Genasense in Advanced Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00522834|Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT00540969|Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases|TERMINATED|PHASE3|INTERVENTIONAL","NCT00671918|Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00769704|Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00779714|Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00796445|A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor|TERMINATED|PHASE3|INTERVENTIONAL","NCT00864253|A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01006252|A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT01006980|A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01106040|Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes|COMPLETED|PHASE3|INTERVENTIONAL","NCT01223248|Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT01245062|GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01259934|Nordic Adjuvant IFN Melanoma Trial|COMPLETED|PHASE3|INTERVENTIONAL","NCT01264874|MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients|TERMINATED|PHASE3|INTERVENTIONAL","NCT01272609|Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01274338|Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT01307397|A Study of Vemurafenib in Participants With Metastatic Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01359956|Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01368276|An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01515189|Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab|COMPLETED|PHASE3|INTERVENTIONAL","NCT01546571|Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients|TERMINATED|PHASE3|INTERVENTIONAL","NCT01584648|A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01597908|Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01667419|A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01682083|Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).|COMPLETED|PHASE3|INTERVENTIONAL","NCT01689519|A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01721772|Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01785316|The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases|COMPLETED|PHASE3|INTERVENTIONAL","NCT01826864|Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT01866319|Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01875653|Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT01909453|Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01989572|Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery|COMPLETED|PHASE3|INTERVENTIONAL","NCT02224781|Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT02263508|Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT02362594|Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT02388906|Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT02427893|Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT02545075|A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine|COMPLETED|PHASE3|INTERVENTIONAL","NCT02599402|Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT02714218|A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT02752074|A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02829775|A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02905266|A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma|COMPLETED|PHASE3|INTERVENTIONAL"]}]}